LUNG Earnings & Financial Statements
Pulmonx Corporation
$1.78
+$0.02(+1.14%)
49
Overall
60
Value
36
Tech
52
Quality
Market Cap
$76.45M
Volume
284.94K
52W Range
$1.13 - $2.89
Target Price
$3.40
LUNG earnings and financial statements: Pulmonx Corporation's income statement, balance sheet and cash flow statement, annual and quarterly.
LUNG Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $90.50M | $83.79M | $68.67M | $53.66M | $48.42M |
| Cost of revenue | $23.36M | $21.79M | $17.92M | $13.80M | $12.79M |
| Operating income | -$53.66M | -$57.70M | -$61.94M | -$58.64M | -$47.30M |
| EBITDA | -$47.67M | -$49.00M | -$55.99M | -$55.99M | -$46.62M |
| Net income | -$54.00M | -$56.39M | -$60.84M | -$58.92M | -$48.66M |
| EPS (diluted) | $-1.33 | $-1.44 | $-1.60 | $-1.59 | $-1.35 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $129.29M | $162.85M | $177.78M | $193.68M | $235.17M |
| Total liabilities | $75.17M | $77.04M | $59.47M | $39.67M | $41.93M |
| Shareholders’ equity | $54.12M | $85.81M | $118.31M | $154.01M | $193.24M |
| Cash and equivalents | $69.75M | $70.91M | $83.55M | $101.74M | $148.48M |
| Long-term debt | $55.05M | $52.52M | $36.20M | $21.08M | $7.02M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$32.40M | -$31.50M | -$37.60M | -$45.08M | -$41.39M |
| Capital expenditure | -$452.0K | -$1.45M | -$807.0K | -$1.32M | -$3.67M |
| Free cash flow | -$32.85M | -$32.95M | -$38.42M | -$46.40M | -$45.06M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LUNG | $1.78 | +1.1% | 284.94K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |